Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-20

Clinical Trial Update: Oxytocin Dosage to Decrease Induction Duration [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating oxytocin dosage to shorten induction duration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxytocin (Oxytocin)

Snippet

Sponsor: University of Arizona | Conditions: Obesity, Labor, Induced | Phase 4 | Status: COMPLETED | Results posted: 2022-12-20